SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001140361-24-002118
Filing Date
2024-01-12
Accepted
2024-01-12 16:01:35
Documents
14
Period of Report
2023-10-30
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A ef20018550_8ka.htm   iXBRL 8-K/A 38041
2 EXHIBIT 99.1 ef20018550_ex99-1.htm EX-99.1 1235948
3 EXHIBIT 99.2 ef20018550_ex99-2.htm EX-99.2 623742
  Complete submission text file 0001140361-24-002118.txt   2167233

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA gyre-20231030.xsd EX-101.SCH 3908
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20231030_lab.xml EX-101.LAB 22547
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20231030_pre.xml EX-101.PRE 16073
8 EXTRACTED XBRL INSTANCE DOCUMENT ef20018550_8ka_htm.xml XML 4207
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

IRS No.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-51173 | Film No.: 24532043
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)